Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241628 | 0.86 | DAO (0.39) | DAOOPRM1OPRK1CSF1RHDAC3 | |
| SCHEMBL30936605 | 0.74 | CSF1R (0.41) | DAOOPRM1OPRK1CSF1ROPRD1 | |
| SCHEMBL6882363 | 0.74 | OPRM1 (0.41) | DAOOPRM1OPRK1CSF1ROPRD1 | |
| SCHEMBL30936589 | 0.72 | CSF1R (0.40) | DAOOPRM1OPRK1CSF1ROPRD1 | |
| SCHEMBL6790881 | 0.72 | CES2 (0.38) | — | |
| SCHEMBL2668587 | 0.70 | ALOX5 (0.41) | TRPA1 | |
| SCHEMBL4085676 | 0.70 | KMT2A (0.43) | OPRM1OPRK1HDAC1HDAC6 | |
| SCHEMBL15998771 | 0.69 | TRPV1 (0.46) | DAOOPRM1OPRK1CSF1ROPRD1 | |
| SCHEMBL5715884 | 0.69 | ESR1 (0.38) | — | |
| SCHEMBL12204358 | 0.69 | ALOX5 (0.40) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | DAO 1452/4885OPRM1 3701/4885OPRK1 1848/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | DAO 1452/4885OPRM1 3701/4885OPRK1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.